Insight Molecular Diagnostics (IMDX) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed QuidelOrtho (QDEL) over the past year, losing 10.9% versus a loss of 55.5%. Over five years, QDEL leads with a -90.3% price change compared with -95.2% for IMDX. QuidelOrtho is the larger company by market cap ($875.0 million vs $109.5 million), about 8.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | QDEL |
|---|---|---|
| Share price | $3.35 | $12.76 |
| Market cap | $109.50M | $875.02M |
| 1-day change | +2.01% | +2.82% |
| YTD return | -56.27% | -56.55% |
| 1-year return | -10.87% | -55.46% |
| 5-year return | -95.18% | -90.32% |
| Forward P/E | — | 8.85 |
| EPS (TTM) | $-1.52 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $35.58 |
| 52-week low | $2.42 | $9.92 |
| Distance from 52-week high | -60.68% | -64.14% |
| Analyst consensus | none | hold |
| Avg. price target upside | +146.56% | +14.97% |
| Average volume | 232.87K | 1.51M |
| Shares outstanding | 32.72M | 68.58M |
| Employees | 55 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QuidelOrtho is about 8.0 times larger than Insight Molecular Diagnostics by market value ($875.02M vs $109.50M).
- IMDX has outperformed QDEL by 44.6 percentage points over the past year.
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
IMDX vs QDEL FAQ
Which is bigger, Insight Molecular Diagnostics or QuidelOrtho?
QuidelOrtho (QDEL) is larger, with a market capitalization of $875.02M compared with $109.50M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, IMDX or QDEL?
IMDX returned -10.87% over the past 12 months, compared with -55.46% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.